NCT00833339

Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder

Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: James J. Peters Veterans Affairs Medical Center · Federal
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators propose to conduct a randomized double-blind, parallel-group, placebo-controlled trial of mifepristone in veterans with military-related posttraumatic stress disorder (PTSD). This study will examine the clinical, neuropsychological, and neuroendocrine effects of short-term treatment of mifepristone (600 mg/day for one week) to determine if this treatment is efficacious in improving PTSD symptoms, cognitive functioning, or other related clinical measures. Additionally, the investigators will observe whether baseline neuroendocrine activity, or other clinical or neuropsychological factors predict the response to mifepristone, and whether mifepristone-induced changes in neuroendocrine activity are associated with treatment outcome.

Conditions

• Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	mifepristone	600 mg/day x 1 week
DRUG	placebo	placebo

Timeline

• Start date: 2008-05-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2009-02-02
• Last updated: 2015-04-01

Locations

1 site across 1 country: United States